ArticleBMC gastroenterology2025
A comprehensive analysis of percutaneous liver biopsy characteristics and pathological manifestations in a large patient cohort (2009-2024).
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between hemoglobin-to-red blood cell distribution width ratio trajectory patterns and in-hospital mortality in critically ill patients with cirrhosis: a retrospective cohort study based on MIMIC-IV and eICU-CRD.BMC medical informatics and decision making · 2026Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to analyze the characteristics of patients undergoing percutaneous liver biopsies and investigate the pathological manifestations of four major liver diseases across different age groups.
methodsA retrospective analysis was conducted of 4,717 liver pathology reports from 2009 to 2024. The study population comprised 4,188 patients who underwent liver biopsies, with 408 patients receiving two biopsies and 50 patients who underwent three or more procedures. Most of biopsies (4,171) were performed between 2013 and 2023. Disease categorization, temporal distribution, and pathological manifestations across different age groups were assessed employed descriptive statistics, trend analyses, and graphical representations.
resultsSince 2020, a gradual increase has been observed in the proportion of cases involving concurrent hepatitis B complicated by metabolic-associated steatohepatitis (MASLD), along with an elevation in the incidence of MASLD alone. Pathological manifestations varied considerably across different age groups. Patients with hepatitis B complicated by MASLD exhibited disease exacerbation in middle age, with both liver inflammation and fibrosis grading worsening as age advanced. Furthermore, within the same age bracket, the severity of inflammation and the extent of fibrosis were more pronounced in cases where chronic hepatitis B was combined with MASLD compared to those with isolated chronic hepatitis B or MASLD.
conclusionThis study offers a comprehensive analysis of the characteristics and pathological manifestations of patients who underwent percutaneous liver biopsies over a 15-year period. The findings underscore the varying pathological manifestations across different age groups for the four major liver diseases and emphasize the necessity for tailored therapeutic interventions, particularly for patients with concurrent hepatitis B and MASLD, as antiviral therapy alone may be inadequate. Further research is warranted to explore optimal management strategies for these patient subpopulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.